AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience (Al-COVE)

CareDx

Status: Unknown

Conditions: COVID-19; Solid Organ Transplant Rejection

Study type: Observational

Funder types: Industry

Identifiers

NCT04341103

Al-COVE

Details and patient eligibility

About

The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19

Full description

An observational case series of patients with solid organ transplants who have been admitted with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression management balancing the treatment of sepsis and avoiding allograft rejection.

Enrollment: 500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed diagnosis of COVID-19

Exclusion Criteria: